Patients from 22+ countriesPlan your visit →
lutetium-therapy
Considering Lu-177 Therapy · 21 Aug 2026

Does Lu-177 PSMA Therapy Cause Permanent Nerve Damage?

Nerve pain during Lu-177 PSMA therapy almost always traces to one of three identifiable causes - not to the therapy itself. Understanding which one applies to you changes how your care team can help.

Editorial oversight by Arpan Talwar·Founder, Art of Healing CancerUpdated 21 Aug 2026
Does Lu-177 PSMA Therapy Cause Permanent Nerve Damage?

This article is for people with metastatic castration-resistant prostate cancer (mCRPC) who are considering or already receiving Lu-177 PSMA therapy, also called lutetium Lu-177 vipivotide tetraxetan or Pluvicto. If you have noticed numbness, tingling, or shooting pain in your hands or feet, you want to know whether the treatment is to blame and whether things will get better.

The short answer: Lu-177 PSMA therapy is not known to directly cause peripheral neuropathy. But nerve pain is common in men at this stage of prostate cancer, and it nearly always has a cause you can identify. Knowing what is actually causing the symptoms helps your care team respond.

Quick answer: Lutetium Lu-177 vipivotide tetraxetan does not appear to be a primary cause of peripheral neuropathy. Nerve pain that appears or worsens during Lu-177 PSMA treatment most often comes from one of three sources: lasting nerve damage from prior taxane chemotherapy, pressure on nerve roots from bone metastases, or a temporary pain flare in the first weeks after an injection.

What Is Peripheral Neuropathy?

Peripheral neuropathy means damage or irritation of the nerves outside the brain and spinal cord. These nerves carry signals between your body and your central nervous system. When they are disrupted, they send wrong signals.

Common symptoms include:

  • Numbness or reduced feeling, often starting in the feet
  • Tingling or a pins-and-needles sensation in the hands or feet
  • Burning or sharp pain along a limb
  • Weakness in the hands or feet
  • Trouble with balance or fine movements like fastening buttons

The cause of neuropathy matters because it shapes what will happen. Neuropathy from a drug works very differently from neuropathy caused by a tumor pressing on a nerve. Your care team needs to know which one you have before deciding what to do.

Does Lu-177 PSMA Therapy Itself Cause Neuropathy?

Not typically. In the VISION trial, the large study that supported the FDA approval of lutetium Lu-177 vipivotide tetraxetan, the most common side effects reported in more than 20 percent of patients were fatigue, dry mouth, nausea, anemia, decreased appetite, and constipation. Peripheral neuropathy was not among the primary or most frequently reported adverse effects.

Lu-177 PSMA delivers targeted beta radiation directly to PSMA-expressing cancer cells throughout the body. Unlike taxane chemotherapy, which disrupts cellular structures found everywhere including in nerve fibers, Lu-177 PSMA does not have a known way to directly damage peripheral nerves.

That said, if you notice new or clearly worsening nerve symptoms after a cycle, tell your care team. The cause needs to be found before anything else can be done about it.

The Most Common Cause: Prior Chemotherapy

Most patients who reach the stage where Lu-177 PSMA therapy is offered have already been through taxane-based chemotherapy, usually docetaxel, sometimes cabazitaxel. Taxane drugs work against cancer by disrupting cell division, but the same process harms sensory nerve fibers throughout the body.

The result is called chemotherapy-induced peripheral neuropathy, or CIPN. Docetaxel causes a predominantly sensory neuropathy, meaning it mainly affects how things feel rather than how muscles move. The severity tends to be related to how many cycles a patient received and the total dose accumulated over the course of treatment.

CIPN from docetaxel usually starts in the feet and may spread to the hands. It often feels like numbness, tingling, or a persistent burning sensation. Some patients also notice difficulty with balance or with fine tasks.

Importantly, this nerve damage can persist for months or years after chemotherapy ends. Sensory nerve fiber damage may be slow to repair and may not fully resolve in every patient.

If you had numbness or tingling during or after docetaxel and those symptoms were still present when you began Lu-177 PSMA therapy, pre-existing CIPN probably explains it. The important point is that Lu-177 PSMA is not known to make taxane-related neuropathy worse. The drug works by a completely different mechanism from the one that caused harm to your nerves during chemotherapy.

Before you start treatment, document what nerve symptoms you already have and tell your care team what you experience. This gives you a clear baseline so any changes during Lu-177 PSMA cycles can be tracked accurately and attributed correctly.

The Second Cause: Bone Metastases Pressing on Nerves

In advanced prostate cancer, bone metastases are very common and the spine is one of the most frequent sites. When cancer cells grow inside or around vertebrae, they can press on the spinal cord or on the nerve roots that branch off from it. This is called nerve root compression.

Nerve root compression can cause pain that travels down an arm or leg, weakness in specific muscle groups, and in more serious cases, numbness in the inner thighs, groin, or buttocks, or loss of bladder or bowel control.

If you develop sudden weakness in your legs, new difficulty walking, or any change in bladder or bowel control, contact your oncology team immediately or go to an emergency department. These are urgent signs of cord compression that require prompt medical attention regardless of where you are in treatment.

For less severe nerve compression, such as shooting leg pain or one-sided numbness, your team will want to know whether the bone lesion causing pressure is being targeted by Lu-177 PSMA. If that lesion responds to treatment and shrinks, the nerve compression and related pain may ease over time. You can read more about how this therapy approaches bone disease in our article on bone pain during Lu-177 PSMA therapy and when to expect relief.

The Third Cause: A Temporary Pain Flare After Injection

Some patients notice a short-term increase in pain, including nerve-type pain, in the days or first couple of weeks after a Lu-177 PSMA injection. This is sometimes called a treatment pain flare.

This may happen because treated lesions may produce a brief inflammatory response before cancer cells begin dying off. A flare does not mean the treatment is failing. In some cases it may reflect the treatment reaching its intended target.

A flare is typically short-lived. Most people who experience one find that symptoms peak within a few days and settle within two weeks. Our article on pain flare after Lu-177 PSMA therapy explains what to expect and what your care team may suggest to manage it during those weeks.

How to Tell the Three Causes Apart

The pattern of your symptoms can help your care team identify the source:

  • Pre-existing CIPN: Symptoms were present before Lu-177 PSMA started. Usually symmetrical - both feet or both hands equally affected. Mainly numbness and tingling rather than sharp or shooting pain. Stable or slowly improving since chemotherapy ended.
  • Bone metastasis nerve compression: Often one-sided. May include pain that shoots down an arm or leg, or weakness in a specific muscle group. May worsen with movement or certain positions. Linked to areas where you have known bone lesions.
  • Treatment pain flare: Appeared in the first one to two weeks after an injection. Affects areas where you already had pain or known cancer deposits. Improves on its own within days to two weeks without any change in treatment.

Keep a brief daily symptom log with where the pain or numbness is, when it started or changed, and what it feels like on a scale from 1 to 10. A record helps your team much more in a clinic visit than a general description, and it helps them see whether symptoms are improving, stable, or worsening between cycles.

Does Lu-177 PSMA Make Pre-Existing Neuropathy Worse?

Lutetium Lu-177 vipivotide tetraxetan does not appear to directly worsen pre-existing chemotherapy-induced peripheral neuropathy. The drug works through a completely different mechanism from taxane drugs. It does not interfere with the cellular processes that taxanes disrupt in nerve fibers.

That said, each patient's starting point is different. If neuropathy from prior chemotherapy was already significant when you began considering Lu-177 PSMA therapy, your oncologist and nuclear medicine physician will assess whether treatment is appropriate and what monitoring you need. If you are uncertain how your pre-existing nerve symptoms affect your eligibility or your experience during treatment, you can speak with the Art of Healing Cancer nuclear-medicine team before you start treatment.

Nutritional Support for Nerve Health During Treatment

No supplement prevents or reverses chemotherapy-induced peripheral neuropathy. However, some patients discuss nutritional support with their dietitian as part of general care during Lu-177 PSMA treatment. B-complex vitamins, particularly B1, B6, and B12, play a role in nerve function, and deficiencies are not uncommon in patients who have gone through several lines of cancer treatment. Before adding anything to your routine, check with your care team first.

Questions to Ask Your Care Team

Before starting Lu-177 PSMA therapy, or at any point during treatment if nerve symptoms appear or worsen, consider asking:

  • Do my current neuropathy symptoms affect my eligibility or the safety of this treatment?
  • Which of my bone lesions are close to the spine or nerve roots?
  • What changes in my symptoms would be a red flag requiring an urgent call or visit?
  • Should my nerve symptoms be formally assessed at each cycle visit?

If you want to understand your eligibility more fully before you choose a treatment center, our article on getting a second opinion on Lu-177 PSMA eligibility explains what documents to prepare and how the review process works.

To have your case reviewed by a team with experience in Lu-177 PSMA therapy for mCRPC, including how pre-existing neuropathy affects treatment planning, you can send your PSMA-PET report and treatment history through the Lutetium Therapy contact form. If Lu-177 isn't right for you, the team can also point you toward alternative options worth discussing with your oncologist.

When to Talk to Your Doctor

Contact your oncologist or care team promptly if you notice any of the following:

  • New numbness, tingling, or pain that is clearly worse than before treatment started
  • Weakness in the legs or feet that affects walking or balance
  • Any change in bladder or bowel control
  • Numbness in the groin, inner thighs, or buttocks
  • A sudden increase in pain anywhere in the body within the first two weeks of a new injection

Sudden leg weakness or bladder and bowel changes are urgent. If you cannot reach your care team quickly, go to an emergency department.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.

Frequently asked questions

Does Lu-177 PSMA therapy cause peripheral neuropathy?

Not typically. In the VISION trial, the most common side effects of lutetium Lu-177 vipivotide tetraxetan were fatigue, dry mouth, nausea, anemia, and decreased appetite. Peripheral neuropathy was not among the primary expected adverse effects. If neuropathy appears or worsens during treatment, the cause is usually pre-existing damage from prior taxane chemotherapy, nerve compression from a bone metastasis, or a temporary post-injection pain flare - not the Lu-177 PSMA therapy itself.

I had numbness and tingling from docetaxel before starting Lu-177 PSMA. Will it get worse?

There is no established evidence that Lu-177 PSMA directly worsens chemotherapy-induced peripheral neuropathy. Lu-177 PSMA works through a completely different mechanism from taxane drugs like docetaxel. Document your current symptoms carefully before starting treatment so any changes can be tracked accurately. Tell your oncologist and nuclear medicine team about your existing neuropathy before your first cycle.

How can I tell if nerve pain is from bone metastases or from the treatment itself?

Nerve pain from bone metastases is often one-sided and may shoot down an arm or leg. It is usually linked to known sites of bone disease and may worsen with movement or certain positions. A post-injection pain flare appears in the first one to two weeks after a cycle and typically improves on its own. Pre-existing neuropathy from chemotherapy is usually symmetrical and was present before treatment started. A symptom log noting location, timing, and character of pain helps your care team distinguish between these three patterns.

What nerve symptoms after Lu-177 PSMA require urgent medical attention?

Sudden leg weakness, new difficulty walking, numbness in the inner thighs or groin, or any change in bladder or bowel control are potentially urgent signs of spinal cord or nerve root compression. Do not wait for a scheduled appointment. Contact your oncology team immediately or go to an emergency department if these symptoms appear. This applies at any stage of treatment.

Is neuropathy from docetaxel permanent?

The outlook varies considerably between patients. Some people see gradual improvement after chemotherapy ends, while others have symptoms that persist for months or years. Full resolution is not guaranteed for everyone. No drug is currently proven to reliably reverse CIPN, though symptoms often partially improve with time after the offending drug has been stopped.

Could Lu-177 PSMA therapy actually help nerve pain caused by bone metastases?

Possibly. Lu-177 PSMA delivers targeted radiation to PSMA-expressing cancer cells in bone lesions. If a lesion that is pressing on a nerve root shrinks in response to treatment, the nerve compression - and any pain associated with it - may ease over time. This is not guaranteed and depends on how well individual lesions respond. Your care team can assess which lesions are near nerve structures and monitor changes during and after treatment.

Have a specific question about your situation?

A free conversation with a patient navigator can help you understand whether Lutetium therapy fits your case, what questions to ask your oncologist, and which centers might be right for you.

Navigators don't diagnose or prescribe. They help you have better conversations with the doctors who do.